Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabirnetug in early Alzheimer's disease
2023-509807-34-00Phase 2Authorised
- Sponsor
- Acumen Pharmaceuticals, Inc.
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Sabirnetug with Placebo (2 arms). Primary endpoint: Change from Baseline to Week 80 in the iADRS score. Planned start Aug 2024; status: authorised.
02
Drugs
sabirnetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2023-509807-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509807-34-00.